Inhibition of NGLY1 Inactivates the Transcription Factor Nrf1 and Potentiates Proteasome Inhibitor Cytotoxicity

Proteasome inhibitors are used to treat blood cancers such as multiple myeloma (MM) and mantle cell lymphoma. The efficacy of these drugs is frequently undermined by acquired resistance. One mechanism of proteasome inhibitor resistance may involve the transcription factor Nuclear Factor, Erythroid 2 Like 1 (NFE2L1, also referred to as Nrf1), which responds to proteasome insufficiency or pharmacological inhibition by upregulating proteasome subunit gene expression. This “bounce-back” response is achieved through a unique mechanism. Nrf1 is constitutively translocated into the ER lumen, N-glycosylated, and then targeted for proteasomal degradation via the ER-associated degradation (ERAD) pathway. Proteasome inhibition leads to accumulation of cytosolic Nrf1, which is then processed to form the active transcription factor. Here we show that the cytosolic enzyme N-glycanase 1 (NGLY1, the human PNGase) is essential for Nrf1 activation in response to proteasome inhibition. Chemical or genetic disruption of NGLY1 activity results in the accumulation of misprocessed Nrf1 that is largely excluded from the nucleus. Under these conditions, Nrf1 is inactive in regulating proteasome subunit gene expression in response to proteasome inhibition. Through a small molecule screen, we identified a cell-active NGLY1 inhibitor that disrupts the processing and function of Nrf1. The compound potentiates the cytotoxicity of carfilzomib, a clinically used proteasome inhibitor, against MM and T cell-derived acute lymphoblastic leukemia (T-ALL) cell lines. Thus, NGLY1 inhibition prevents Nrf1 activation and represents a new therapeutic approach for cancers that depend on proteasome homeostasis.

[1]  K. Kitajima,et al.  Identification of peptide:N-glycanase activity in mammalian-derived cultured cells. , 1993, Biochemical and biophysical research communications.

[2]  Aaron Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway , 1994, Cell.

[3]  A. Jaiswal,et al.  Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Kolstø,et al.  Small Maf proteins interact with the human transcription factor TCF11/Nrf1/LCR-F1. , 1996, Nucleic acids research.

[5]  N. Thornberry,et al.  Inhibition of Human Caspases by Peptide-based and Macromolecular Inhibitors* , 1998, The Journal of Biological Chemistry.

[6]  A. Kolstø,et al.  Interaction of the CNC-bZIP factor TCF11/LCR-F1/Nrf1 with MafG: binding-site selection and regulation of transcription. , 1998, Nucleic acids research.

[7]  Aaron Ciechanover,et al.  The ubiquitin–proteasome pathway: on protein death and cell life , 1998, The EMBO journal.

[8]  Y. Kan,et al.  Targeted disruption of the ubiquitous CNC‐bZIP transcription factor, Nrf‐1, results in anemia and embryonic lethality in mice , 1998, The EMBO journal.

[9]  R. Sternglanz,et al.  PNG1, a Yeast Gene Encoding a Highly Conserved Peptide:N-Glycanase , 2000, The Journal of cell biology.

[10]  A. Burlingame,et al.  Epoxide electrophiles as activity-dependent cysteine protease profiling and discovery tools. , 2000, Chemistry & biology.

[11]  S Toba,et al.  Selective targeting of lysosomal cysteine proteases with radiolabeled electrophilic substrate analogs. , 2000, Chemistry & biology.

[12]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[13]  Matthew Bogyo,et al.  A Role for the Protease Falcipain 1 in Host Cell Invasion by the Human Malaria Parasite , 2002, Science.

[14]  A. Ciechanover,et al.  The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. , 2002, Physiological reviews.

[15]  N. Munshi,et al.  NF-κB as a Therapeutic Target in Multiple Myeloma* , 2002, The Journal of Biological Chemistry.

[16]  A. Burlingame,et al.  Chemical Approaches for Functionally Probing the Proteome* , 2002, Molecular & Cellular Proteomics.

[17]  H. Ploegh,et al.  A role for N‐glycanase in the cytosolic turnover of glycoproteins , 2003, The EMBO journal.

[18]  J. Adams,et al.  The proteasome: structure, function, and role in the cell. , 2003, Cancer treatment reviews.

[19]  S. Yao,et al.  Solid-phase synthesis of peptide vinyl sulfones as potential inhibitors and activity-based probes of cysteine proteases. , 2003, Organic letters.

[20]  H. Ploegh,et al.  Using a small molecule inhibitor of peptide: N-glycanase to probe its role in glycoprotein turnover. , 2004, Chemistry & biology.

[21]  J. Adams.  The proteasome: a suitable antineoplastic target , 2004, Nature Reviews Cancer.

[22]  A. Jaiswal,et al.  Nrf3 Negatively Regulates Antioxidant-response Element-mediated Expression and Antioxidant Induction of NAD(P)H:Quinone Oxidoreductase1 Gene* , 2004, Journal of Biological Chemistry.

[23]  H. Ploegh,et al.  Yeast N‐glycanase distinguishes between native and non‐native glycoproteins , 2004, EMBO reports.

[24]  M. Bogyo,et al.  Solid‐Phase Synthesis of Double‐Headed Epoxysuccinyl Activity‐Based Probes for Selective Targeting of Papain Family Cysteine Proteases , 2005, Chembiochem : a European journal of chemical biology.

[25]  Matthew Bogyo,et al.  Activity-based probes that target diverse cysteine protease families , 2005, Nature chemical biology.

[26]  Candy S. Lee,et al.  Liver-specific inactivation of the Nrf1 gene in adult mouse leads to nonalcoholic steatohepatitis and hepatic neoplasia. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Bycroft,et al.  The PUB Domain Functions as a p97 Binding Module in Human Peptide N-Glycanase* , 2006, Journal of Biological Chemistry.

[28]  L. Boise,et al.  Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. , 2006, Blood.

[29]  H. Schindelin,et al.  Site-specific Labeling of Cytoplasmic Peptide:N-Glycanase by N,N′-Diacetylchitobiose-related Compounds* , 2006, Journal of Biological Chemistry.

[30]  Tadashi Suzuki,et al.  Fluorescently labeled inhibitor for profiling cytoplasmic peptide:N-glycanase. , 2007, Glycobiology.

[31]  S. Demo,et al.  Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. , 2005, Blood.

[32]  S. Elmore.  Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.

[33]  A. Derjuga,et al.  Endoplasmic reticulum association and N‐linked glycosylation of the human Nrf3 transcription factor , 2007, FEBS letters.

[34]  Matthew Bogyo,et al.  Identification of proteases that regulate erythrocyte rupture by the malaria parasite Plasmodium falciparum. , 2008, Nature chemical biology.

[35]  Kerstin Amann,et al.  The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis , 2008, Nature Medicine.

[36]  H. Overkleeft,et al.  Synthesis and biological evaluation of a chitobiose-based peptide N-glycanase inhibitor library. , 2009, The Journal of organic chemistry.

[37]  H. Schindelin,et al.  Structural and mutational studies on the importance of oligosaccharide binding for the activity of yeast PNGase. , 2008, Glycobiology.

[38]  S. Cullen,et al.  Caspase activation pathways: some recent progress , 2009, Cell Death and Differentiation.

[39]  A. Ciechanover,et al.  Targeting proteins for destruction by the ubiquitin system: implications for human pathobiology. , 2009, Annual review of pharmacology and toxicology.

[40]  E. Krüger,et al.  Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. , 2010, Molecular cell.

[41]  R. Deshaies,et al.  Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. , 2010, Molecular cell.

[42]  J. Chan,et al.  Role of Nrf1 in antioxidant response element-mediated gene expression and beyond. , 2010, Toxicology and applied pharmacology.

[43]  S. Mohan,et al.  Targeted disruption of nuclear factor erythroid-derived 2-like 1 in osteoblasts reduces bone size and bone formation in mice. , 2010, Physiological genomics.

[44]  T. Hunter,et al.  Ubiquitylation and proteasomal degradation of the p21Cip1, p27Kip1 and p57Kip2 CDK inhibitors , 2010, Cell cycle.

[45]  R. Voll,et al.  Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia Gravis , 2011, The Journal of Immunology.

[46]  A. Fukamizu,et al.  Central nervous system‐specific deletion of transcription factor Nrf1 causes progressive motor neuronal dysfunction , 2011, Genes to cells : devoted to molecular & cellular mechanisms.

[47]  E. Huang,et al.  Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration , 2011, Proceedings of the National Academy of Sciences.

[48]  M. Bogyo,et al.  Chemical genetic screen identifies Toxoplasma DJ-1 as a regulator of parasite secretion, attachment, and invasion , 2011, Proceedings of the National Academy of Sciences.

[49]  A. Bertolotti,et al.  Failure of Amino Acid Homeostasis Causes Cell Death following Proteasome Inhibition , 2012, Molecular cell.

[50]  Jianmin Wang,et al.  The resistance mechanisms of proteasome inhibitor bortezomib , 2013, Biomarker Research.

[51]  H. Sasakawa,et al.  NMR characterization of the interaction between the PUB domain of peptide:N‐glycanase and ubiquitin‐like domain of HR23 , 2012, FEBS letters.

[52]  P. Cresswell,et al.  Deglycosylation-dependent fluorescent proteins provide unique tools for the study of ER-associated degradation , 2013, Proceedings of the National Academy of Sciences.

[53]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[54]  S. Grossman,et al.  p53 Ubiquitination and proteasomal degradation. , 2013, Methods in molecular biology.

[55]  David R McIlwain,et al.  Caspase functions in cell death and disease. , 2013, Cold Spring Harbor perspectives in biology.

[56]  Megan C. Garland,et al.  Small-molecule inhibition of a depalmitoylase enhances Toxoplasma host-cell invasion , 2013, Nature chemical biology.

[57]  Q. Dou,et al.  Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. , 2014, Current cancer drug targets.

[58]  J. Hayes,et al.  Transcription Factor Nrf1 Is Topologically Repartitioned across Membranes to Enable Target Gene Transactivation through Its Acidic Glucose-Responsive Domains , 2014, PloS one.

[59]  R. Deshaies,et al.  p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition , 2013, bioRxiv.

[60]  Max A. Horlbeck,et al.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.

[61]  A. Goldberg,et al.  Proteasome-Mediated Processing of Nrf1 Is Essential for Coordinate Induction of All Proteasome Subunits and p97 , 2014, Current Biology.

[62]  R. Deshaies,et al.  Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy , 2014, BMC Biology.

[63]  Michael P. Snyder,et al.  Mutations in NGLY1 cause an inherited disorder of the endoplasmic reticulum–associated degradation pathway , 2014, Genetics in Medicine.

[64]  H. Freeze,et al.  NGLY1 mutation causes neuromotor impairment, intellectual disability, and neuropathy. , 2015, European journal of medical genetics.

[65]  L. Yao,et al.  Transcription factor Nrf1 is negatively regulated by its O‐GlcNAcylation status , 2015, FEBS letters.

[66]  Daniel E. Johnson.  The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors. , 2015, Endocrine-related cancer.

[67]  Takehiro Suzuki,et al.  Endo-β-N-acetylglucosaminidase forms N-GlcNAc protein aggregates during ER-associated degradation in Ngly1-defective cells , 2015, Proceedings of the National Academy of Sciences.

[68]  P. Cresswell,et al.  A congenital disorder of deglycosylation: biochemical characterization of N‐glycanase 1 deficiency in patient fibroblasts (607.3) , 2014, Glycobiology.

[69]  Tadashi Suzuki.  The cytoplasmic peptide:N-glycanase (Ngly1)-basic science encounters a human genetic disorder. , 2015, Journal of biochemistry.

[70]  H. Ichijo,et al.  The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction , 2016, eLife.

[71]  J. Hagenbuchner,et al.  Targeting transcription factors by small compounds--Current strategies and future implications. , 2016, Biochemical pharmacology.

[72]  Gary Ruvkun,et al.  Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1 , 2016, eLife.

[73]  Max A. Horlbeck,et al.  Compact and highly active next-generation libraries for CRISPR-mediated gene repression and activation , 2016, eLife.

[74]  Jürgen Roth,et al.  Quality control of glycoprotein folding and ERAD: the role of N-glycan handling, EDEM1 and OS-9 , 2016, Histochemistry and Cell Biology.

[75]  A. Goldberg,et al.  Reply to Vangala et al.: Complete inhibition of the proteasome reduces new proteasome production by causing Nrf1 aggregation , 2016, Current Biology.

[76]  Tadashi Suzuki,et al.  The cytoplasmic peptide:N-glycanase (NGLY1) - Structure, expression and cellular functions. , 2016, Gene.

[77]  M. Gertz,et al.  A practical review on carfilzomib in multiple myeloma , 2016, European journal of haematology.

[78]  J. Chan,et al.  Nuclear Factor Erythroid-2 Like 1 (NFE2L1): Structure, function and regulation. , 2016, Gene.

[79]  Yiguo Zhang,et al.  Molecular and cellular basis for the unique functioning of Nrf1, an indispensable transcription factor for maintaining cell homoeostasis and organ integrity. , 2016, The Biochemical journal.

[80]  M. Bogyo,et al.  Design of Selective Substrates and Activity-Based Probes for Hydrolase Important for Pathogenesis 1 (HIP1) from Mycobacterium tuberculosis , 2016, ACS infectious diseases.

[81]  Eric S. Lander,et al.  Gene Essentiality Profiling Reveals Gene Networks and Synthetic Lethal Interactions with Oncogenic Ras , 2017, Cell.

[82]  S. Wakana,et al.  Lethality of mice bearing a knockout of the Ngly1-gene is partially rescued by the additional deletion of the Engase gene , 2017, PLoS genetics.

[83]  Ellen F. Macnamara,et al.  Prospective phenotyping of NGLY1-CDDG, the first congenital disorder of deglycosylation , 2016, Genetics in Medicine.

[84]  R. Orlowski,et al.  Proteasome inhibitors in cancer therapy , 2017, Nature Reviews Clinical Oncology.

[85]  T. Natsume,et al.  Multiple regulatory mechanisms of the biological function of NRF3 (NFE2L3) control cancer cell proliferation , 2017, Scientific Reports.